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Evaluation of leptomeningeal contrast enhancement using pre-and postcontrast subtraction 3D-FLAIR imaging in multiple sclerosis. AJNR Am J Neuroradiol 2018; 39: 642-647. The high sensitivity of magnetic resonance (MR) imaging in depicting brain and spinal cord demyelinating plaques has made this technique the most important paraclinical tool in current use not only for the diagnosis of multiple sclerosis (MS) but also for understanding the natural history of the disease, and monitoring and predicting the efficacy of diseasemodifying treatments. However, MR imaging is suboptimal for detecting cortical demyelination, a frequent pathological finding in MS, which is particularly prominent in the progressive phases of the disease and closely associated to physical disability and cognitive impairment. In recent years, several studies have demonstrated that cortical demyelination, particularly those involving the subpial gray matter, colocalize with prominent leptomeningeal inflammation, which is linked to cortical atrophy and disability progression and exacerbated in a significant proportion of cases by the presence of B cell follicle-like structures. 1 For that reason, different studies have analyzed the value of conventional MR imaging in detecting this inflammatory component, which is shown as focal leptomeningeal enhancement (LME) on contrast-enhanced T2-weighted fluid-attenuated inversion-recovery sequence (T2-FLAIR). 2 In their essays, Absinta and Reich, and Wattjes and Killestein, provide some convincing arguments in favor and against implementing MR imaging protocols for assessing LME in clinical practice. Absinta and Reich indicate that this imaging finding could be considered as a biomarker of gray matter atrophy and cortical demyelination, and valuable to predict disability progression and to monitor new or future treatments targeting meningeal inflammation. Based on that, they recommend to use an optimized MR imaging protocol to detect this radiological feature in clinical practice. 3 However, Wattjes and Killestein point out that there is still not enough evidence to establish the clinical and prognostic consequences of meningeal inflammation detection on MR imaging in individual MS patients, and therefore still some research efforts are required before recommending imaging of meningeal inflammation as part of the routine MR imaging protocol. 4 In MS MR imaging protocols, it has been proposed to acquire T2-FLAIR images after gadolinium injection. 5 The rational for this recommendation is to use the "dead time" between gadolinium injection and acquisition of contrast-enhanced T1-weighted images, in which a minimum delay of 5 minutes to 10 minutes is highly recommended to achieve a good sensitivity in detecting acute inflammatory demyelinating lesions.
With this strategy, the total acquisition time of the MR protocol is not lengthened, and can improve the conspicuousness of enhancing lesions, because of the effect of gadolinium on shortening the T1 relaxation times in these lesions further increases their signal intensity on T2-FLAIR images. An additional advantage of this strategy, is the possibility of identifying LME in MS patients. This LME has been demonstrated in 1%-50% of patients with MS on contrastenhanced T2-FLAIR images acquired at 3T. [6] [7] [8] [9] This wide range can be explained by technical differences in the MR imaging parameters used (2D or 3D acquisition, slice thickness, dose and relaxivity of the gadolinium-based contrast agent used, and the delay between contrast injection and acquisition of the T2-FLAIR sequence), and in the proportion of patients with a progressive phase of the disease. This frequency can be as high as 90%, matching the frequency described in histopathologic studies, 1 when contrast-enhanced T2-FLAIR sequence is acquired with high-resolution 3D sequences on a 7T magnet, and with a delay of 20 minutes after contrast injection. 10 However, this MR imaging strategy is difficult, if not impossible, to implement in clinical practice, as the vast majority of clinical MR imaging studies are performed on 1.5 or 3T magnets. The time delay used also represents an issue, as T2-FLAIR sequence is commonly acquired immediately after gadolinium injection, to fill the required time gap between injection and acquisition of the contrast-enhanced T1-weighted image. An alternative could be to use this "dead time" to acquire the standard T2-weighted sequence and any other required sequences, such as susceptibility-weighted or diffusion-weighted imaging, and move the T2-FLAIR sequence to the end of the MR imaging protocol. This would mean that contrast-enhanced T1-weighted and T2-FLAIR (ideally obtained with a 3D acquisition) will be acquired 10 minutes and 15 minutes after gadolinium injection, which is probably a good compromise between optimal MR strategy and a reasonable total acquisition time.
In summary, there is no doubt that MR imaging detection of LME, represents a novel and attractive in vivo marker of inflammation and associated subpial demyelination, which could be used to predict the clinical outcome of MS patients and for testing the efficacy of new drugs aimed at eliminating this inflammatory component of the disease. However, before considering a new MR imaging protocol that optimizes the detection of this imaging feature in clinical practice, more data are required to provide definite evidence of its prognostic value, and its role in monitoring and predicting treatment response in individual MS patients. Meanwhile, in order to obtain this evidence, it can be recommended to implement an optimized strategy aimed to detect meningeal inflammation as part of the routine MR imaging protocol, at least in those institutions with research interest in À Rovira demonstrating the potential role of LME as a new imaging biomarker of inflammation and cortical damage in MS patients.
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